Radiopharm Theranostics Limited
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Radiopharm Theranostics Limited (ASX:RAD; NASDAQ:RADX), a clinical-stage radiotherapeutics company, develops innovative radiopharmaceutical products for diagnostic and therapeutic applications targeting cancer indications with high unmet medical needs, including solid tumors such as non-small cell lung cancer, breast cancer, pancreatic cancer, brain metastases, and prostate cancer. The company's pipeline features therapeutic candidates RAD204, a PD-L1-targeted nanobody radiolabeled with Lutetium-177 in Phase 1 for PD-L1-positive solid tumors; RAD202, a HER2-targeted nanobody radiolabeled with Lutetium-177 in Phase 1 for HER2-positive solid tumors; and RV-01, a B7-H3-targeted monoclonal antibody radiolabeled with Lutetium-177 advancing toward Phase 1/2a through a joint venture with MD Anderson Cancer Center; alongside diagnostic agents RAD101, a short chain fatty acid small molecule radiolabeled with Fluorine-18 in Phase 2b for brain metastases, and RAD301, an integrin αvβ6-targeted peptide radiolabeled with Gallium-68 in Phase 1 for pancreatic cancer, with preclinical programs RAD402 (KLK3-targeted monoclonal antibody with Terbium-161 for prostate cancer) and RAD302 (integrin αvβ6-targeted peptide therapeutic with Lutetium-177). Founded in 2021 and headquartered in Carlton, Australia, Radiopharm operates globally with clinical trials in the United States and Australia, supported by subsidiaries including Radiopharm Theranostics (USA), Inc. Recent developments include a A$35 million capital raise in October 2025 to fund clinical trials and extend cash runway into 2027; FDA Fast Track Designation for RAD101 in June 2025 and Investigational New Drug clearance for RV-01 in July 2025; Dose Safety Monitoring Committee approval in May 2025 to escalate dosing in RAD204's Phase 1 trial; first patient dosing in RAD202's Phase 1 HEAT trial in June 2025; supply agreements with ITM Isotope Technologies Munich SE for non-carrier-added Lutetium-177 and Cyclotek for Terbium-161 doses; and dual-listing on NASDAQ as RADX in 2024.
Company News
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next?
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
Radiopharm Theranostics Reports Business Update
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study
Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX)
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Average Rating of “Buy” by Brokerages
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages
RAD Increases Ownership in Radiopharm Ventures to 87.5%